ABEO Живые сигналы | Максимизируйте прибыль с Getagraph.com

Купить 105729 min ago

@ $6.00

Выпущен: 14 февр. 2024 @ 22:22

Доходность: -45.67%

Предыдущий сигнал: февр. 14 - 21:08

Предыдущий сигнал: Продать

Доходность: -5.73 %

Live Chart Being Loaded With Signals

Commentary (26 апр. 2024 @ 23:00):

Stats
Объем за сегодня	1.19M
Средний объем	519 739
Рыночная капитализация	89.18M
EPS	$0 ( 2024-04-03 )
Дата следующего отчета о доходах	( $-0.470 ) 2024-05-09
Last Dividend	$3 706.25 ( 2000-03-31 )
Next Dividend	$0 ( N/A )
P/E	-1.290
ATR14	$0.0140 (0.43%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-25	O'malley Brendan M.	Buy	8 600	Common stock
2024-04-25	Vazzano Joseph Walter	Buy	5 608	Common stock
2024-03-15	Vazzano Joseph Walter	Sell	703	Common stock
2024-03-04	O'malley Brendan M.	Sell	183	Common stock
2024-02-06	Seshadri Vishwas	Buy	20 000	Common Stock

INSIDER POWER
82.26
Last 95 transactions
Buy: 4 761 439 \| Sell: 620 827

Объем Корреляция

Длинно: 0.22 (neutral)

Кратко: -0.62 (weak negative)

Signal:(40.398) Neutral

Abeona Therapeutics Inc Корреляция

10 Самые положительные корреляции
NVDA	0.94
COOL	0.939
BOTZ	0.938
OPRA	0.935
SVAC	0.932
AVGO	0.924
SMCI	0.923
ADVM	0.923
DFH	0.922
TQQQ	0.921

10 Самые отрицательные корреляции
AMRB	-0.953
LWAC	-0.916
NETE	-0.915
SOPA	-0.913
ONCR	-0.909
PHCF	-0.907
SRAC	-0.9
PRDO	-0.89
QTEK	-0.888
AGFS	-0.887

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Abeona Therapeutics Inc Корреляция - Валюта/Сырье

-0.03
( neutral )

0.23
( neutral )

0.00
( neutral )

0.11
( neutral )

0.42
( neutral )

Abeona Therapeutics Inc Финансовые показатели

Annual	2023
Выручка:	$3.50M
Валовая прибыль:	$302 000 (8.63 %)
EPS:	$-2.53

FY	2023
Выручка:	$3.50M
Валовая прибыль:	$302 000 (8.63 %)
EPS:	$-2.53

FY	2022
Выручка:	$1.41M
Валовая прибыль:	$964 000 (68.18 %)
EPS:	$-4.05

FY	2021
Выручка:	$3.00M
Валовая прибыль:	$3.00M (100.00 %)
EPS:	$-21.57

Financial Reports:

No articles found.

Abeona Therapeutics Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Abeona Therapeutics Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$3 706.25	2000-03-31
Last Dividend	$3 706.25	2000-03-31
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$3 706.25	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-04-28)

$0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2000	$3.00	0.03%
2001	$0	0.00%
2002	$0	0.00%
2003	$0	0.00%
2004	$0	0.00%
2005	$0	0.00%
2006	$0	0.00%
2007	$0	0.00%
2008	$0	0.00%
2009	$0	0.00%
2010	$0	0.00%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-15.48	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.847	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-3.34	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	4.15	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	4.10	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.103	1.500	4.98	7.47	[0.2 - 2]
debtRatioTTM	0.0844	-1.500	8.59	-10.00	[0 - 0.6]
interestCoverageTTM	-115.31	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-1.448	2.00	-0.483	-0.965	[0 - 30]
freeCashFlowPerShareTTM	-1.461	2.00	-0.731	-1.461	[0 - 20]
debtEquityRatioTTM	0.364	-1.500	8.54	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.0863	1.000	-1.895	-1.895	[0.2 - 0.8]
operatingProfitMarginTTM	-13.77	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-6.85	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.0547	0.800	-2.97	-2.38	[0.5 - 2]
Total Score				-2.42

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-1.537	1.000	-0.256	0	[1 - 100]
returnOnEquityTTM	-3.34	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-1.461	2.00	-0.487	-1.461	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-1.448	2.00	-0.483	-0.965	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.0712	1.500	-2.86	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-10.57	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.65

Abeona Therapeutics Inc

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.